Name: Flutamide
Brand: Selleck Chemicals
SKU: S1908
Availability: InStock
Rating: 5 (20 reviews)

Jump to

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES
Other Androgen Receptor Inhibitors	Bavdegalutamide (ARV-110) RU58841 EPI-001 Galeterone Cyproterone Acetate 3,3'-Diindolylmethane JNJ-63576253 (TRC-253) Ailanthone Proxalutamide (GT0918) Rezvilutamide

Solubility

In vitro
Batch:

DMSO : 55 mg/mL (199.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 55 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.750mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 55 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.350mg/ml (4.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 27 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	276.21	Formula	C₁₁H₁₁F₃N₂O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	13311-84-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	SCH-13521			SMILES	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Androgen Receptor 55 nM(Ki)
In vitro	Flutamide (Eulexin) is an antiandrogen drug. Its active metabolite, Flutamide-OH, directly binds at rat anterior pituitary androgen receptor with K_i values of 55 nM. This compound does not affect the proliferation of an androgen-sensitive clone of the mouse mammary carcinoma Shionogi SC-l 15 cells in culture, shows only antiandrogenic effect, but not androgenic effect. It provides treatment for prostate cancer when used along with leuprolide.
Kinase Assay	Androgen Receptor Assay
Kinase Assay	Aliquots of 100 μl cytosol are incubated at 0-4°C for 18 h with 100 μl of the indicated saturating concentration of [³H]T in the presence or absence of increasing concentrations of nonlabeled T, DHT, flutamide (FLU) or this compound (FLU-OH). At the end of the incubation, free and bound T are separated by the addition of 200 μl dextran-coated charcoal (1 % charcoal, 0.1% dextran T-70, 0.1% gelatin, 1.5 mM EDTA and 50 mM Tris (pH 7.4)) for 15 min before centrifugation at 2300 × g for another 15 min at 0-4°C. Aliquots (350 μl) of the supernatant are transferred to scintillation vials with 10 ml of an aqueous counting solution before counting in a Beckman LS 330 counter.
In vivo	Flutamide causes a markedly reduction in rat ventral prostate weight from 319 mg to 245 mg. A combination of this compound and LHRH agonist induces an additive effect with a decrease in prostate weight to 101 mg, and an marked drop in prostatic ODC activity.
References	[1] https://pubmed.ncbi.nlm.nih.gov/3956856/ [2] https://pubmed.ncbi.nlm.nih.gov/2462135/ [3] https://pubmed.ncbi.nlm.nih.gov/2503724/ [4] https://pubmed.ncbi.nlm.nih.gov/2838689/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-17)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04513717	ACTIVE_NOT_RECRUITING	Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8	NRG Oncology	2021-01-21	PHASE3
NCT03678025	RECRUITING	Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8	SWOG Cancer Research Network	2018-09-24	PHASE3
NCT06694350	NOT_YET_RECRUITING	Head and Neck Squamous Cell Carcinoma	Zhejiang Provincial People's Hospital	2024-12	PHASE2
NCT01786265	ACTIVE_NOT_RECRUITING	Prostate Adenocarcinoma; Recurrent Prostate Carcinoma	M.D. Anderson Cancer Center	2013-02-05	PHASE2
NCT05050084	ACTIVE_NOT_RECRUITING	Prostate Adenocarcinoma	NRG Oncology	2021-12-06	PHASE3
NCT04787744	RECRUITING	Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer	VA Office of Research and Development	2021-07-01	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Flutamide Androgen Receptor antagonist

Chemical Structure

Molecular Weight: 276.21